cyclophosphamide + doxorubicin + paclitaxel + sorafenib

This is a combination chemotherapy regimen consisting of four drugs: - Cyclophosphamide, an alkylating agent that crosslinks DNA, leading to cell death. - Doxorubicin, an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and apoptosis. - Paclitaxel, a taxane that stabilizes microtubules and prevents their depolymerization during cell division, thereby inhibiting mitosis. - Sorafenib, a multikinase inhibitor targeting several tyrosine protein kinases including RAF kinases (part of the RAS/RAF/MEK/ERK pathway), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), FLT3, RET proto-oncogene protein (RET), and c-KIT. Sorafenib inhibits tumor cell proliferation and angiogenesis. This combination has been investigated primarily in high-risk or node-positive early-stage breast cancer as adjuvant therapy. The regimen typically involves sequential administration of doxorubicin plus cyclophosphamide followed by paclitaxel with concurrent or subsequent addition of oral sorafenib[1][2][3][6]. The main goal is to enhance antitumor efficacy by combining cytotoxic chemotherapy with targeted inhibition of tumor signaling pathways.

Other names

AC-T plus sorafenibdoxorubicin/cyclophosphamide and paclitaxel plus sorafenib